Molecular Profile Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name	ARID1A dec exp
Gene Variant Detail	ARID1A dec exp (no effect)
Relevant Treatment Approaches

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 18 of 18 entries

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
ARID1A dec exp	breast cancer	conflicting		Talazoparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Talzenna (talazoparib) selectively inhibited growth and induced apoptosis in breast cancer cells with knock-down of ARID1A in culture, and inhibited tumor growth in ARID1A-deficient breast cancer cell line xenograft models (PMID: 26069190).	26069190
ARID1A dec exp	ovarian cancer	predicted - sensitive		Buthionine sulfoximine	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ovarian cancer cells with ARID1A-deficiency via knockdown were sensitive to treatment with Buthionine sulfoximine (BSO), demonstrating decreased cell survival and reduced colony formation in culture and tumor growth suppression in cell-line xenograft models (PMID: 30686770).	30686770
ARID1A dec exp	ovarian cancer	predicted - sensitive		APR-246	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ovarian cancer cells with ARID1A-deficiency via knockdown were sensitive to treatment with APR-246, demonstrating decreased cell survival and reduced colony formation in culture and tumor growth suppression in cell-line xenograft models (PMID: 30686770).	30686770
ARID1A dec exp	ovarian cancer	sensitive		GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, GSK126 inhibited growth of ovarian cancer cells with knockdown of ARID1A expression in culture (PMID: 25686104).	25686104
ARID1A dec exp	breast cancer	sensitive		Veliparib	Preclinical - Cell culture	Actionable	In a preclinical study, Veliparib (ABT-888) inhibited colony formation of human mammary epithelial cells and inhibited proliferation of a human breast cancer cell line after knockdown of ARID1A in culture (PMID: 26069190).	26069190
ARID1A dec exp	breast cancer	sensitive		Rucaparib	Preclinical - Cell culture	Actionable	In a preclinical study, Rubraca (rucaparib) inhibited colony formation of human mammary epithelial cells and inhibited proliferation of a human breast cancer cell line after knockdown of ARID1A in culture (PMID: 26069190).	26069190
ARID1A dec exp	ovarian cancer	sensitive		Talazoparib	Preclinical - Cell culture	Actionable	In a preclinical study, knockdown of ARID1A resulted in increased sensitivity to Talzenna (talazoparib) in ovarian cancer cells in culture (PMID: 26069190).	26069190
ARID1A dec exp	breast cancer	conflicting		Talazoparib	Preclinical - Cell culture	Actionable	In a preclinical study, human mammary epithelial cells with knockdown of ARID1A demonstrated resistance to Talzenna (talazoparib) when compared to parental cells in culture (PMID: 29669295).	29669295
ARID1A dec exp	ovarian clear cell carcinoma	predicted - sensitive		Molibresib	Preclinical - Cell culture	Actionable	In a preclinical study, knockdown of ARID1A resulted in increased sensitivity to Molibresib (GSK525762) in ovarian clear cell carcinoma cell lines in culture (PMID: 29760405).	29760405
ARID1A dec exp	urinary bladder cancer	sensitive		GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, GSK126 inhibited viability of bladder cancer cell lines with ARID1A knockdown in culture (PMID: 35852858).	35852858
ARID1A dec exp	urinary bladder cancer	sensitive		CPI-1205	Preclinical - Cell culture	Actionable	In a preclinical study, CPI-1205 inhibited viability of bladder cancer cell lines with ARID1A knockdown in culture (PMID: 35852858).	35852858
ARID1A dec exp	urinary bladder cancer	sensitive		Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, Tazverik (tazemetostat) inhibited viability of bladder cancer cell lines with ARID1A knockdown in culture (PMID: 35852858).	35852858
ARID1A dec exp	urinary bladder cancer	sensitive		MAK683	Preclinical - Cell culture	Actionable	In a preclinical study, MAK683 inhibited viability of bladder cancer cell lines with ARID1A knockdown in culture (PMID: 35852858).	35852858
ARID1A dec exp	urinary bladder cancer	sensitive		Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, Piqray (alpelisib) inhibited viability of bladder cancer cell lines with ARID1A knockdown in culture (PMID: 35852858).	35852858
ARID1A dec exp	urinary bladder cancer	sensitive		Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, Pictilisib (GDC-0941) inhibited viability of bladder cancer cell lines with ARID1A knockdown in culture (PMID: 35852858).	35852858
ARID1A dec exp	urinary bladder cancer	sensitive		Dactolisib	Preclinical - Cell culture	Actionable	In a preclinical study, Dactolisib (BEZ235) inhibited viability of bladder cancer cell lines with ARID1A knockdown in culture (PMID: 35852858).	35852858
ARID1A dec exp	urinary bladder cancer	sensitive		GSK126 + Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of GSK126 and Pictilisib (GDC-0941) synergistically inhibited viability of bladder cancer cell lines with ARID1A knockdown in culture (PMID: 35852858).	35852858
ARID1A dec exp	breast cancer	sensitive		Olaparib	Preclinical	Actionable	In a preclinical study, Lynparza (olaparib) inhibited colony formation of human mammary epithelial cells and inhibited proliferation of a human breast cancer cell line after knockdown of ARID1A in culture (PMID: 26069190).	26069190

Showing 1 to 18 of 18 entries

Filter rows: